Gatepath

Gatepath is a biotechnology company focused on the discovery and development of small molecule medicines that modulate autophagy to treat serious diseases. Incubated by Versant Ventures and launched through its Ridgeline Discovery engine, the company targets "gatekeeper" proteins that regulate the initiation and flux of the autophagy pathway. By precisely controlling cellular recycling processes, Gatepath aims to address high-need indications in neurodegeneration, metabolic disorders, and oncology. The company's approach leverages a proprietary platform to identify novel chemical entities capable of restoring proteostasis and cellular health. Gatepath operates with a team of experts in protein homeostasis and drug discovery, utilizing state-of-the-art screening and medicinal chemistry.